Amgen reported new VESALIUS‑CV data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% when added to standard therapy in high‑risk patients without prior heart attack or stroke. The trial, published in the New England Journal of Medicine and presented at the American Heart Association meeting, also showed a 36% reduction in first heart attacks. Investigators reported fewer coronary deaths, myocardial infarctions and strokes and a reduction in revascularization procedures, reinforcing Repatha’s role beyond secondary prevention. The results expand the clinical profile of PCSK9 inhibition and may influence prescribing decisions for primary prevention in severely dyslipidemic patients.